modified endothelial progenitor cell-derived exosomes

Modified endothelial progenitor cell-derived exosomes are extracellular vesicles (EVs) isolated from endothelial progenitor cells (EPCs) that have been genetically or chemically altered to enhance their therapeutic properties. These modifications can include the enrichment of specific microRNAs, proteins, or other bioactive molecules within the exosome cargo to improve efficacy in tissue repair and regeneration. The mechanism of action involves delivering reparative signals to target tissues—such as promoting angiogenesis, reducing fibrosis, modulating inflammation, and enhancing cellular proliferation and differentiation. Preclinical studies have demonstrated benefits in cardiovascular diseases (e.g., myocardial infarction), kidney pathology, diabetes-related complications, bone healing, brain regeneration after injury or stroke, and lung repair. Modified EPC-exosomes are being explored for their ability to orchestrate complex regenerative processes by transferring functional genetic material and proteins that activate endogenous repair pathways[1][2].

Other names

modified EPC-derived exosomesengineered EPC-exosomesmodified EPC-EVs